STOCK TITAN
  1. Home
  2. News
  3. DHR

Danaher Corp. - DHR STOCK NEWS

Welcome to our dedicated news page for Danaher (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Danaher's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Danaher's position in the market.

News
Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock
Rhea-AI Summary
Danaher Corporation expects to complete the separation of Veralto Corporation on September 30, 2023. Danaher stockholders will receive one share of Veralto common stock for every three shares of Danaher common stock they hold on the Record Date. Fractional shares of Veralto common stock will be sold in the open market. No action is required by Danaher stockholders to receive the distributed shares of Veralto common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
News
Danaher Releases 2023 Sustainability Report
Rhea-AI Summary
Danaher Corporation has published its 2023 Sustainability Report, highlighting the company's sustainability program and achievements. The report details key accomplishments in product innovation, team building, and environmental protection. Danaher updated its product development tools to consider sustainability needs, increased diversity in its workforce, maintained pay equity, and developed tools to reduce greenhouse gas emissions. The company also assessed the sustainability practices of its suppliers and aims to increase coverage in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
-
News
BetterInvesting™ Magazine Update on Danaher Corp. and Alphabet Inc.
Rhea-AI Summary
Danaher Corp. (NYSE: DHR) has been named the 'Stock to Study' and Alphabet Inc. (NASDAQ: GOOG) as the 'Undervalued Stock' by the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine. This announcement highlights the importance of quarterly earnings presentations and the use of the BetterInvesting Stock Selection Guide for assessing a company's sales, earnings, and profitability. Investors can find more details in the October 2023 issue of BetterInvesting Magazine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
News
Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
Rhea-AI Summary
Beckman Coulter unveils the DxI 9000 Access Immunoassay Analyzer, a clinical diagnostics tool that addresses laboratory demands for speed, reliability, reproducibility, quality, and menu expansion. The analyzer has the capability to develop sensitive and clinically relevant assays, providing new opportunities to quantify trace amounts of biomarkers in blood samples. The collaboration with Fujirebio will support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in neurodegenerative diseases. The DxI 9000 also excels in improving clinical laboratory operations with zero daily maintenance requirements and automated safeguards to prevent erroneous reporting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
News
Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance
Rhea-AI Summary
Beckman Coulter Diagnostics has received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer. The analyzer is designed for small-to-medium-sized laboratories and uses standardized assays and reagents across Beckman Coulter's portfolio of AU clinical chemistry analyzers. It has a broad menu of 120-plus assays and has been independently verified for quality performance. Diagnostic testing guides 70% of medical decisions, and the DxC 500 AU Chemistry Analyzer aims to improve accuracy and reliability of results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
clinical trial
-
News
Danaher Reports Second Quarter 2023 Results
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) announced its second quarter 2023 results, reporting a net earnings of $1.1 billion, or $1.49 per diluted common share, and a non-GAAP adjusted diluted net earnings per common share of $2.05. Revenues decreased 7.5% year-over-year to $7.2 billion, with a 7.0% non-GAAP core revenue decrease. Operating cash flow for the quarter was $1.9 billion, and non-GAAP free cash flow was $1.6 billion. The Company anticipates low-single digits year-over-year decrease in non-GAAP base business core revenue for the third quarter 2023, and low-single digits year-over-year growth for the full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
earnings
News
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics
Rhea-AI Summary
Fujirebio (ticker: FUJI) and Beckman Coulter announced a partnership to develop blood-based neurodegenerative disease assays, addressing the global unmet clinical need for Alzheimer's Disease diagnostics. With over 100 drug candidates under development, the partnership aims to accelerate the deployment of new biomarkers to laboratories and clinicians worldwide, leveraging Beckman Coulter's high-sensitivity immunoassay analyzers and Fujirebio's assay technology. The collaboration will focus on menu expansion on Beckman Coulter’s Access Family of Immunoassay Analyzers, with initial efforts targeting the DxI 9000 Access Immunoassay Analyzer and the widespread installed base of Access Family Immunoassay Analyzers. Fujirebio has obtained FDA authorization for β-amyloid pathology assessment using cerebral spinal fluid and is continuing to develop and expand the menu with additional biomarkers obtained through the recent acquisition of ADx NeuroSciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
partnership
-
News
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
Rhea-AI Summary
Fujirebio and Beckman Coulter Diagnostics announce a partnership to develop blood-based diagnostic capabilities for neurodegenerative diseases, addressing the global unmet clinical need for Alzheimer's Disease diagnostics. The collaboration leverages Fujirebio's expertise in neurodegenerative disease assays and Beckman Coulter's high sensitivity, high throughput, global installed base of Access Family of Immunoassay Analyzers. This partnership aims to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases, with a focus on Alzheimer's Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
partnership
-
News
Danaher Schedules Second Quarter 2023 Earnings Conference Call
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
earnings
News
Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
Stock DHR logo
Danaher Corp.

NYSE:DHR

DHR Rankings

#50 Ranked by Market Cap
#3077 Ranked by Stock Gains
#2019 Ranked by Dividends

DHR Stock Data

177.69B
659.36M
10.76%
81.69%
0.86%
Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
Manufacturing
Link
US
Washington

About DHR

Danaher Corporation is an American globally diversified conglomerate founded by brothers Stephen and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.